COVID-19 Vaccines: AstraZeneca’s UK Study Not Good Enough For US FDA Authorization, Slaoui Says
Executive Summary
Operation Warp Speed chief scientific advisor confirms doubts about the Phase III data from two UK and Brazil studies; says efficacy results in US trials of AstraZeneca and Janssen vaccines expected by mid-January.
You may also be interested in...
AstraZeneca Vaccine May Only Gain EU Approval In Under 70s
AZ and the EU are at loggerheads over supplies of the COVID-19 vaccine. On top of that, its marketing authorization will present dilemmas.
Oxford’s Vaccine Results Still Puzzle, AZ Expects Not To File With FDA
Partners hope non-US regulators will authorize early and then await later readouts to clarify vaccine's profile, but FDA is expected to hold out for US trial data.
Deal Watch: Merck & Co. Looks To Advance NASH Ambitions With Aligos
Newly public Aligos will team with Merck & Co. on oligonucleotide therapies for NASH. Maze Therapeutics launches ophthalmology and CV-focused spinouts with Alloy and BridgeBio.